Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SMART Path program. The updated application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated research and development program for PC111, a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis. This represents 80% co-financing for the program.
The amendment extends the option condition deadline to August 31, 2026, and the exercise period to September 30, 2026, aligning with the anticipated three- to four-month grant review timeline as the company advances PC111 toward early clinical development and human proof of concept. The strategic timing of these developments suggests Scinai is positioning itself for significant milestones in its immunology pipeline while maintaining financial flexibility.
For investors and industry observers, this news represents a dual strategic move with substantial implications. The extension of the PinCell acquisition option provides Scinai with continued access to potential assets while deferring financial commitments until after the grant decision. More significantly, the €12 million grant application, if approved, would provide substantial non-dilutive funding at a critical juncture in PC111's development. This funding model is particularly attractive in the current biotech investment climate, where capital efficiency and non-dilutive financing are increasingly valued.
The therapeutic focus of PC111 addresses significant unmet medical needs in rare autoimmune skin conditions. Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disease, while Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis represent severe cutaneous adverse reactions with high mortality rates. Successful development of PC111 could provide new treatment options for patients with these challenging conditions, potentially transforming the standard of care in dermatology and immunology.
The company's latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI. For more information about MissionIR, which distributed this announcement, please visit https://www.MissionIR.com.
From an industry perspective, Scinai's approach exemplifies how biopharmaceutical companies are leveraging European grant programs to advance promising therapies while managing financial risk. The SMART Path program specifically targets innovative projects with commercial potential, suggesting that PC111 has been recognized as having both scientific merit and market viability. The 80% co-financing rate is particularly notable, as it significantly reduces the company's financial burden while advancing a potentially valuable asset.
The implications of this announcement extend beyond Scinai's immediate financial planning. Successful grant approval could accelerate PC111's development timeline, potentially bringing a new treatment option to market sooner for patients with limited therapeutic alternatives. For the biotech sector, it demonstrates how strategic use of non-dilutive funding sources can support pipeline advancement while preserving shareholder value. The alignment of the option extension with the grant review timeline shows sophisticated operational planning that balances opportunity with financial prudence.
